Xeris Biopharma reports notice of allowance from USPTO

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced on December 1, 2025, that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.’s U.S. patent application covering XP-8121, a novel product candidate. The Notice of Allowance indicates that the application meets the requirements for patentability and is expected to issue as a U.S. patent following standard administrative procedures. The allowed claims specifically relate to the formulation of XP-8121.

XP-8121 is an investigational, ready-to-use liquid formulation of levothyroxine sodium designed for once-weekly subcutaneous injection using Xeris’ proprietary XeriSol® technology. The formulation aims to address limitations associated with oral levothyroxine, such as variable absorption and drug-food interactions. Xeris continues to pursue additional layers of IP protection in the levothyroxine (LT4) technology space.

John Shannon, Chief Executive Officer of Xeris, emphasized that the patent represents a key milestone in strengthening the company’s IP protection around the XP-8121 program and highlights the XeriSol® platform capabilities in developing challenging drug formulations.

Xeris currently markets three products: Recorlev® for endogenous Cushing’s syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis. The company also has a pipeline of development programs, including XP-8121, which is Phase 3-ready, and early-stage programs leveraging XeriSol® and XeriJect® platforms.

The company’s patent strategy includes a “castle/moat” approach, with a focus on securing early and broad IP protection. As of April 2023, Xeris held 178 total patents globally, with 33 issued in the U.S. and 128 applications pending. The newly allowed patent for XP-8121 adds to this growing portfolio and supports Xeris’ long-term innovation goals.